| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 02/14/2002 | WO2002011763A1 Cd40 antagonists for use in treating psoriasis and other inflammatory skin conditions |
| 02/14/2002 | WO2002011752A1 Use of gli1 gene |
| 02/14/2002 | WO2002011667A2 Pharmaceutical compositions and methods useful for modulating angiogenesis |
| 02/14/2002 | WO2001073018A3 Human tap-like protein (transporter associated in antigen processing/presentation) |
| 02/14/2002 | WO2001072264A3 Pro-liposomal encapsulated preparations (iv) |
| 02/14/2002 | WO2001064874A3 Low density liprotein binding proteins and their use in diagnosing and treating atherosclerosis |
| 02/14/2002 | WO2001064247A3 Method of treating cancer with anti-neurotrophin agents |
| 02/14/2002 | WO2001062954A8 Stearoyl-coa desaturase to identify triglyceride reducing therapeutic agents |
| 02/14/2002 | WO2001059120A3 Il-17 like molecules and uses thereof |
| 02/14/2002 | WO2001058921A3 Methods and compositions for generating angiostatin |
| 02/14/2002 | WO2001058915A3 Human g-protein chemokine receptor (ccr5) hdgnr10 |
| 02/14/2002 | WO2001057187A3 Novel bone marrow nucleic acids and polypeptides |
| 02/14/2002 | WO2001055302A3 Nucleic acids, proteins, and antibodies |
| 02/14/2002 | WO2001051626A3 Novel plasmid expression vectors |
| 02/14/2002 | WO2001051619A3 Genetically modified fibroblast cell |
| 02/14/2002 | WO2001048161A3 Human heparanase-related polypeptide and nucleic acid |
| 02/14/2002 | WO2001042464A3 Human preoptic regulatory factor-2 and uses thereof |
| 02/14/2002 | WO2001042288A3 G-protein coupled receptors |
| 02/14/2002 | WO2001036620A3 Vectors and transgenies with regulatory elements for gene delivery to the liver |
| 02/14/2002 | WO2001036589A3 Human ex vivo immune system |
| 02/14/2002 | WO2001025489A3 Diagnostic and therapeutic uses for a gene differentially expressed in prostate cancer |
| 02/14/2002 | WO2001021771A3 Compositions and methods for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents |
| 02/14/2002 | WO2001014418A3 p193 PROTEINS AND NUCLEIC ACIDS, AND USES THEREOF |
| 02/14/2002 | WO2000065063A9 Nucleic acid vaccines against rickettsial diseases and methods of use |
| 02/14/2002 | WO2000044908A9 Comp/tsp-1, comp/tsp-2 and other tsp chimeric proteins |
| 02/14/2002 | WO2000009552A9 Secreted proteins and polynucleotides encoding them |
| 02/14/2002 | US20020019520 CBFBGA09: a human SL15 homolog |
| 02/14/2002 | US20020019519 KIAA0551 polynucleotides and polypeptides use |
| 02/14/2002 | US20020019515 Novel spoIIIE |
| 02/14/2002 | US20020019362 Treatment of tumors with genetically engineered herpes virus |
| 02/14/2002 | US20020019361 Persistent transgene expression, repeated administration of the therapy |
| 02/14/2002 | US20020019360 Treatment for cardiovascular disease |
| 02/14/2002 | US20020019358 Compositions and methods for in vivo delivery of polynucleotide-based therapeutics |
| 02/14/2002 | US20020019357 Use of magnesium (mg2+) for the preparation of a therapeutic composition for transfection of a polynucleotide into a cell and compositions useful in gene therapy |
| 02/14/2002 | US20020019350 Targeted angiogenesis |
| 02/14/2002 | US20020019041 Storing adenoviruses; preparing liquid composition, maintain liquid at freezing, monitor adenovirues for activity |
| 02/14/2002 | US20020019040 Apoptin-associating protein |
| 02/14/2002 | US20020019030 25324, 50287, 28899, 47007, and 42967 transferase family members and uses therefor |
| 02/14/2002 | US20020019000 Polynucleotides coexpressed with matrix-remodeling genes |
| 02/14/2002 | US20020018995 Detecting brain disorders; obtain sample tissue, monitor tau mutant isoform duplications in cell, compare to wild type, amplification in tau mutant isoforms indicates brain disorders |
| 02/14/2002 | US20020018804 Biological bioadhesive composition and methods of preparation and use |
| 02/14/2002 | US20020018782 Binding to antibodies; prophylaxis, therapy of infections |
| 02/14/2002 | US20020018775 Complexing; separation; gene therapy |
| 02/14/2002 | US20020018769 Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
| 02/14/2002 | US20020018768 Control of gene expression |
| 02/14/2002 | US20020018766 Genes differentially expressed in cancer cells to design cancer vaccines |
| 02/14/2002 | CA2569615A1 Nucleic acid binding compounds containing pyrazolo[3,4-d] pyrimidine analogues of purin-2,6-diamine and their uses |
| 02/14/2002 | CA2453907A1 Association of sim2 with cancer |
| 02/14/2002 | CA2418952A1 A novel member of the lysyl oxidase gene family |
| 02/14/2002 | CA2418936A1 Nucleic acid constructs, vascular cells transformed therewith, pharmaceutical compositions and methods utilizing same for inducing angiogenesis |
| 02/14/2002 | CA2418445A1 Stress proteins and peptides and methods of use thereof |
| 02/14/2002 | CA2418381A1 Pancreatic progenitor cells |
| 02/14/2002 | CA2417982A1 Manipulation of arterial-venous identity |
| 02/14/2002 | CA2417915A1 Her-2/neu fusion proteins |
| 02/14/2002 | CA2417707A1 Sid.rtm. nucleic acids and polypeptides selected from a pathogenic strain of hepatitis c virus and applications thereof |
| 02/14/2002 | CA2417368A1 Suppressor gene |
| 02/14/2002 | CA2416982A1 Lactobacillus rhamnosus polynucleotides, polypeptides and methods for using them |
| 02/14/2002 | CA2415333A1 Adenovirus e1b-55k single amino acid mutants and methods of use |
| 02/14/2002 | CA2406961A1 Cd40 antagonists for use in treating psoriasis and other inflammatory skin conditions |
| 02/14/2002 | CA2386103A1 Vascular endothelial growth factor 2 |
| 02/13/2002 | EP1179587A1 Method for diminishing specific immune reactions |
| 02/13/2002 | EP1179353A1 Antithrombogenic implants with coating of polyphosphazenes and a pharmacologically active agent |
| 02/13/2002 | EP1179350A2 Encapsulated cell system for implantation into the human CNS |
| 02/13/2002 | EP1179340A2 Compositions for the introduction of polyanionic materials into cells |
| 02/13/2002 | EP1179093A1 Expression of ets-domain proteins in cancer |
| 02/13/2002 | EP1179090A1 Nucleic acid probe-based diagnostic assays for prokaryotic and eukaryotic organisms |
| 02/13/2002 | EP1179083A1 Triple hybrid amplicon vector systems to generate retroviral packaging lines |
| 02/13/2002 | EP1179082A2 Improved retroviral production by inhibition of the enveloppe cell receptor |
| 02/13/2002 | EP1179067A1 Neuroprotective properties of gdf-15, a novel member of the tgf-beta superfamily |
| 02/13/2002 | EP1179065A2 Full-length molecules expressed in human tissues |
| 02/13/2002 | EP1179064A2 Secreted polypeptides and corresponding polynucleotides |
| 02/13/2002 | EP1179063A2 Genes expressed in hippocampus |
| 02/13/2002 | EP1179062A2 Nucleic acids and proteins with p53 activity and altered tetramerization domains |
| 02/13/2002 | EP1179061A1 Methods for treating tumors using antiangiogenic compounds |
| 02/13/2002 | EP1179054A2 Use of recombinant parainfluenza viruses (pivs) as vectors to protect against infection and disease caused by piv and other human pathogens |
| 02/13/2002 | EP1179052A2 Serine proteases |
| 02/13/2002 | EP1179015A1 Dna molecules encoding human clax proteins and their soluble fusion proteins |
| 02/13/2002 | EP1178999A2 L-ribo-lna analogues |
| 02/13/2002 | EP1178836A2 Use of chimeric mutational vectors to change endogenous sequences in solid tissues |
| 02/13/2002 | EP1178835A1 Compositions and methods for improving learning and memory |
| 02/13/2002 | EP1178817A2 Molecular interactions in haematopoietic cells |
| 02/13/2002 | EP1178815A1 Death domain containing receptors |
| 02/13/2002 | EP1178785A1 Compositions and methods for identifying antigens which elicit an immune response |
| 02/13/2002 | EP1178722A1 eNOS MUTATIONS USEFUL FOR GENE THERAPY AND THERAPEUTIC SCREENING |
| 02/13/2002 | EP1007671B1 Fanconi-gen ii |
| 02/13/2002 | CN1335890A High efficiency mammalian gene expression vectors that contain exogenous promoter and entire 5' untranslated region in the upstream from start codon for inherent gene as transcription regulatory site |
| 02/13/2002 | CN1335889A Chimeric gene encoding the antigenic determinants of four proteins of L.INFANTUM |
| 02/13/2002 | CN1335398A Recombinant adenovirus vector capable of being duplicated and spread specifcally inside tumor cell |
| 02/13/2002 | CN1335183A Conveying method of reinforced gene vaccine |
| 02/12/2002 | US6346613 An antisense oligonucleotide that hybridizes with a occludin mrna and disrupts tight junctions, to increase cell layer permeability to solutes and drugs |
| 02/12/2002 | US6346608 MecB |
| 02/12/2002 | US6346606 A protein; diagnosis and therapy for tumor diseases, central nervous system diseases, glioblastomas, and breast cancer |
| 02/12/2002 | US6346416 Antisense inhibition of HPK/GCK-like kinase expression |
| 02/12/2002 | US6346415 Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors |
| 02/12/2002 | US6346414 Transposition assembly for gene transfer in eukaryotes |
| 02/12/2002 | US6346409 Tryptophenyl tRNA synthetase from Streptococcus pneumoniae |
| 02/12/2002 | US6346398 Ribozyme or antisense nucleic acid which inhibits synthesis, gene expression and/or stability of messenger rna encoding the flt-1 receptor of human or mouse receptor; treatment of diabetic retinopathy; angiogenesis inhibitors |
| 02/12/2002 | US6346396 MurA |
| 02/12/2002 | US6346393 Polynucleotides encoding a ribonuclease s |
| 02/12/2002 | US6346246 Antibodies that bind human haemopoietic maturation factor |